Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN HUMAN BIOSYNTHETIC

All injection strengths: general benefit

Novolin ge Toronto Penfill · PIN 09853774 · 100U/mL · injection solution-5x3mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02024284 (Cancelled post market, 2026-03-20) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14459

Check Health Canada brand DIN
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Novolin ge Toronto Penfill · DIN 09853774 Manufacturer: Novo Nordisk Canada Inc; listing date 1998-12-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02024284 (Cancelled post market, 2026-03-20) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14459
Check this DIN again

Novolin ge Toronto Penfill: Formulary list price $50.5500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $50.5500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09853774)

Source record
DIN 09853774: Novolin ge Toronto Penfill Raw flags: insOH=Y, sec3=Y Item: 682010019; group id 772; item number 1884; lccId None; manufacturer id NOO Source form: Inj Sol-5x3mL Pk; strength: 100U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $50.5500; ministry $50.5500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09853774 Health Canada record for this brand: DIN 02024284 (Cancelled post market, 2026-03-20) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14459
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09853774
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:10 Insulins (Rapid Acting)) and how they are covered

Matched class: 68:20:10 Insulins (Rapid Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN GLULISINE (DNA ORIGIN), INSULIN INJECTION, HUMAN BIOSYNTHETIC Some products covered without a code (check the product listing): INSULIN ASPART, INSULIN LISPRO 68:20:10 Insulins (Rapid Acting)

INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN ASPART

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5X3mL Pref Pen Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk

INSULIN GLULISINE (DNA ORIGIN)

· 3 products · General benefit · strengths: 100U/mL · Inj 5x3mL Cart ClickStar Pen, Inj Sol-10mL Vial, Inj Sol-5x3mL SoloSTAR Pref Pen

INSULIN INJECTION, HUMAN BIOSYNTHETIC

· 1 products · General benefit · strengths: 500U/mL · Inj Sol-Pref Pen 2x3mL Pk

INSULIN LISPRO

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL, 200U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk, Inj Sol-Pref Pen 5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:10
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetes, emergencies
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN LISPRO & INSULIN LISPRO PROTAMINE INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10 Product monograph Only Novolin®ge Toronto, using intravenous administration, should be used for the treatment of emergencies, such as diabetic coma and pre-coma, and in diabetics undergoing surgery. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10 Product monograph INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC · General benefit 1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10 Product monograph Only Novolin®ge Toronto, using intravenous administration, should be used for the treatment of emergencies, such as diabetic coma and pre-coma, and in diabetics undergoing surgery. PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10 Product monograph INSULIN ASPART · Limited Use, codes 646 (1), General benefit (4) 1 Indications NOVORAPID® (insulin aspart) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. NOVORAPID® should normally be used in regimens together with an intermediate or long-acting insulin. NOVORAPID® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for insulin infusion. PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10 Product monograph INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70% · General benefit  The treatment of adult patients with diabetes mellitus who require insulin for the control of hyperglycemia. PM: https://pdf.hres.ca/dpd_pm/00062479.PDF; date JUL 11, 2017; DIN 02265435; fetched 2026-09-10 Product monograph INSULIN LISPRO · Limited Use, codes 646 (1), General benefit (4) INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02229704; fetched 2026-09-10 Product monograph INSULIN LISPRO & INSULIN LISPRO PROTAMINE · General benefit INDICATIONS AND CLINICAL USE HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Novolin®ge (Insulin, Human Biosynthetic) is indicated for: • The treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia. When administered in appropriate regular doses to patients with diabetes mellitus and who follow a controlled diet and exercise program, Novolin®ge (Insulin, Human Biosynthetic) temporarily restores their ability to metabolize carbohydrates, protein and fats. The Novolin®ge formulations differ with respect to onset, peak and duration of action. These times reflect averages and can vary depending upon the individual patient. The standard time action characteristics are as follows: Novolin®ge Toronto (Insulin Injection, Human Biosynthetic) is a water-clear, colourless, neutral solution of human insulin with a short duration of action. The effect of Novolin®ge Toronto after subcutaneous administration begins after approximately ½ hour, is maximal between 2 ½ and 5 hours and terminates after approximately 8 hours. Novolin®ge NPH (Insulin Isophane, Human Biosynthetic) is a cloudy, neutral suspension of human isophane insulin with an intermediate duration of action. The effect of Novolin®ge NPH begins… https://pdf.hres.ca/dpd_pm/00077108.PDF PM date: JAN 07, 2011 Source product: NOVOLIN GE TORONTO; DIN 02024233; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.